( OTC-BB:TPIV )

News from tapimmune inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Aug 25, 2016, 08:30 ET TapImmune Appoints Michael J. Loiacono as Chief Financial Officer

TapImmune Inc. (OTCMKTS: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based...


Aug 11, 2016, 09:00 ET TapImmune Enters into Definitive Agreements to Raise $8.5 Million From the Exercise of Outstanding Warrants and in a Private Placement from New Investors

TapImmune Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based...


Jul 19, 2016, 08:30 ET TapImmune Appoints Dr. John N. Bonfiglio as President and Chief Operating Officer

TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based...


Jun 21, 2016, 08:30 ET TapImmune Doses First Patient in Its Phase 2 Triple Negative Breast Cancer Trial for Cancer Vaccine TPIV 200

TapImmune,Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based...


Jun 07, 2016, 08:00 ET TapImmune Announces Finalization of License Agreement With Mayo Clinic to Commercialize a HER2neu Vaccine

TapImmune, Inc. (OTCQB: TPIV), a clinical stage cancer immunotherapy company is pleased to announce that the Company has exercised its option...


Jun 06, 2016, 09:00 ET TapImmune to Present at the LD Micro Invitational in Los Angeles on June 7, 2016

TapImmune,Inc. (TPIV), a clinical-stage immune-oncology company specializing in the development of innovative peptide and gene-based...


May 27, 2016, 11:43 ET TapImmune to Present at SeeThruEquity and Marcum Conferences in New York City

TapImmune,Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based...


Apr 28, 2016, 08:30 ET TapImmune to Present at the 3rd Annual Growth Capital Expo in Las Vegas on May 4, 2016

TapImmune,Inc. (TPIV), a clinical-stage immune-oncology company specializing in the development of innovative peptide and gene-based...


Apr 21, 2016, 09:15 ET TapImmune Announces Phase 2 Ovarian Cancer Trial Study with AstraZeneca/MedImmune and Sloan Kettering Cancer Institute

- Study to commence Q2 2016 at Sloan Kettering Institute  - Cancer vaccine and checkpoint inhibitor combination to be evaluated in...


Apr 07, 2016, 08:30 ET TapImmune Completes GMP Manufacturing and Release of TPIV 200 Vaccine

  - Doses for use at Mayo Clinic and other clinical sites  - Stable, easily reconstituted product contains five...


Mar 14, 2016, 08:58 ET TapImmune to Present at 28th Annual ROTH Conference on March 16, 2016

TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and nucleic acid-based...


Feb 18, 2016, 09:00 ET TapImmune Receives Notice of Allowance on U.S. Patent Claims for PolyStart - Next-Generation T-Cell Vaccine

  - Proprietary DNA Expression Vector Technology Developed at TapImmune's Laboratories - PolyStart to Move into Clinical...


Feb 10, 2016, 08:30 ET TapImmune Sponsors 26.2 With DONNA Marathon for Breast Cancer Research and Care

Events & Marathon to take place in Jacksonville, Florida on February 12-14, 2016 TapImmune, Inc. (TPIV), a clinical-stage onco-immunology...


Feb 08, 2016, 08:30 ET TapImmune to Present at Source Capital's 2016 Disruptive Growth & Healthcare Conference on February 10, 2016

TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based...


Feb 03, 2016, 08:30 ET TapImmune Granted Fast Track Designation by U.S. Food & Drug Administration for its Lead Vaccine TPIV 200 in the Treatment of Ovarian Cancer

- Expedites TapImmune's clinical development program for ovarian cancer  - Follows recent Orphan Drug Designation for TPIV 200 in...


Jan 27, 2016, 08:30 ET TapImmune Appoints Frederick G. Wasserman to its Board of Directors

TapImmune Inc. (OTCMKTS: TPIV), a clinical-stage immunology-oncology company specializing in the development of innovative peptide and gene-based...


Jan 07, 2016, 09:15 ET TapImmune to Present at Biotech Showcase 2016 in San Francisco on January 11, 2016

TapImmune, Inc. (TPIV), a clinical-stage immunology-oncology company specializing in the development of innovative peptide and gene-based...


Dec 10, 2015, 08:30 ET TapImmune Presents New Data at San Antonio Breast Cancer Symposium Showing Robust Generation of T-Cell Immunity

- Vaccination with TPIV 100 boosts T-cell immunity to HER2 in HER2+ Breast Cancer Patients   - Provides catalyst to start Phase...


Dec 10, 2015, 08:30 ET TapImmune Presents New Data at San Antonio Breast Cancer Symposium Showing Robust Generation of T-Cell Immunity

- Vaccination with TPIV 100 boosts T-cell immunity to HER2 in HER2+ Breast Cancer Patients   - Provides catalyst to start Phase...


Dec 09, 2015, 15:51 ET U.S. Food & Drug Administration Grants Orphan Drug Designation to TapImmune's TPIV 200 in the Treatment of Ovarian Cancer

TapImmune, Inc. (TPIV), a clinical-stage immunology-oncology company specializing in the development of innovative peptide and gene-based...


Dec 09, 2015, 15:51 ET U.S. Food & Drug Administration Grants Orphan Drug Designation to TapImmune's TPIV 200 in the Treatment of Ovarian Cancer

TapImmune, Inc. (TPIV), a clinical-stage immunology-oncology company specializing in the development of innovative peptide and gene-based...


Dec 07, 2015, 08:30 ET TapImmune to Present New Data at San Antonio Breast Cancer Symposium on December 10, 2015

TapImmune, Inc. (TPIV), a clinical-stage onco-immunology company specializing in the development of innovative peptide and gene-based...


Dec 07, 2015, 08:30 ET TapImmune to Present New Data at San Antonio Breast Cancer Symposium on December 10, 2015

TapImmune, Inc. (TPIV), a clinical-stage onco-immunology company specializing in the development of innovative peptide and gene-based...


Nov 30, 2015, 08:30 ET TapImmune to Present at LD Micro Main Event on December 1, 2015

TapImmune, Inc. (TPIV), a clinical-stage onco-immunology company specializing in the development of innovative peptide and gene-based...


Nov 09, 2015, 09:00 ET Penny Stocks Alerts for Invo Bioscience, Dominovas Energy, Medical Marijuana, Global Equity, TapImmune, and Anavex Life Sciences

Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny...